[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100590991":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":30,"locations":36,"responsibleParty":57,"collaborators":29,"id":60,"slug":29,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":29,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":29,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":29,"overallStatus":38,"whyStopped":29,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Cairo University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Sphenopalatine block group","EXPERIMENTAL","Patients will receive 2 ml of 2% lidocaine using a nasal applicator in each nostril.",[13],"Drug: Sphenopalatine block",{"label":15,"type":10,"description":16,"interventionNames":17},"BOTOX group","Patients will receive Botulinum Toxin Type A 100 units administered in a fixed dose and site paradigm.",[18],"Drug: Botulinum Toxin Type A",[20,26],{"type":21,"name":22,"description":11,"armGroupLabels":23,"otherNames":24},"DRUG","Sphenopalatine block",[9],[25],"Lidocaine",{"type":21,"name":27,"description":16,"armGroupLabels":28,"otherNames":29},"Botulinum Toxin Type A",[15],null,[31],{"name":32,"role":33,"phone":34,"phoneExt":29,"email":35},"Mohamed E Abdel Fattah, MD","CONTACT","00201284475792","mohamed-elsaid@cu.edu.eg",[37],{"facility":5,"status":38,"city":39,"state":29,"zip":40,"country":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"RECRUITING","Cairo","12613","Egypt",{"type":43,"coordinates":44},"Point",[45,46],31.24967,30.06263,{"lat":46,"lon":45},[49,50,53,55],{"name":32,"role":33,"phone":34,"phoneExt":29,"email":35},{"name":51,"role":52,"phone":29,"phoneExt":29,"email":29},"Samuel F Samy, MD","PRINCIPAL_INVESTIGATOR",{"name":54,"role":52,"phone":29,"phoneExt":29,"email":29},"Amany M Abo Taleb, MD",{"name":56,"role":52,"phone":29,"phoneExt":29,"email":29},"Mohammed S ElSharkawy, MD",{"type":52,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":29,"oldOrganization":29},"Mohamed Elsaid Abdel Fattah","Lecturer of Anesthesia, Surgical ICU and Pain Management, Faculty of Medicine, National Cancer Institute, Cairo University, Egypt.","100590991",false,"NCT06974617","Sphenopalatine Block Versus BOTOX in Management of Chronic Migraine","Sphenopalatine Block Versus BOTOX in Management of Chronic Migraine: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Age 18 and 65 years.\n* Both sexes.\n* Chronic migraine. Chronic migraine, defined as headaches on ≥15 days per month for ≥3 months, of which ≥8 days meet criteria for migraine without aura or respond to migraine-specific treatment according to International Classification of Headache Disorders-3 Beta.\n\nExclusion Criteria:\n\n* Patients with medication over use headache.\n* Bleeding disorders.\n* Abnormal neurological examination.\n* History of allergy to local anesthetics or BOTOX.","ALL","18 Years","65 Years",{"count":70,"type":71},64,"ESTIMATED","INTERVENTIONAL",[74],"NA","This trial compares the efficacy and safety of sphenopalatine ganglion block (SPGB) and intramuscular BOTOX injection in chronic migraine.",[77,78,79],"Sphenopalatine Block","BOTOX","Chronic Migraine","2025-05-15",{"date":82,"type":83},"2025-05-16","ACTUAL",{"date":80,"type":83},{"date":86,"type":71},"2025-10-01",{"name":5,"class":6},1]